CVL237 Tablets for APDS/PASLI

NCT06293716 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

PI3K and P110delta Hyperactivation Syndrome

Interventions

DRUG: CVL237 tablets
DRUG: CVL237 placebo tablets

Sponsor

Convalife (Shanghai) Co., Ltd.